Myeloma

Thalidomide's promising future in fighting cancer explored

Published in Blood Weekly, August 5th, 2004

From the late 1950s to the end of 1961, thalidomide was a popular sedative and treatment for morning sickness until it was discovered to cause fetal malformations, which proved fatal within the first year of life in 40% of affected infants.

The drug was never marketed in the United States or approved by the U.S. Food and Drug Administration. But researchers recognized the drug's properties might have cancer-fighting potential. This possibility has driven promising studies into thalidomide's role in fighting blood disorders, such as multiple myeloma, a deadly cancer for which there is no cure.

Mayo Clinic Proceedings has published four studies...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2004-08-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry